CSI Market
Sign In | Register

Evolutionary Genomics Inc (FNAM) Quarterly Cash Flow Statement

Quarterly · GAAP · USD millions
Access FNAM Annual Cash Flow →
Tracking cash flow results across Evolutionary Genomics Inc to Dec 31 2021 helps illustrate how Dec 31 2022's cash generation has responded to changing business conditions.
View historic periods: Download as CSV:
Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.
Quarterly Report, GAAP in USD millions
ITEM 		(Dec 31 2022)
12 Months 		(Sep 30 2022) (Jun 30 2022) (Mar 31 2022) (Dec 31 2021)
Operating Activities
Income-1.93
Depreciation & amortization1.02
Amortization of Other Assets0.00
Extraordinary Item, Gain (Loss), Insurance Assets, Accretion Expense0.00
Restructuring & Impairment Charges0.00
Provision For Loan Losses Expensed0.00
Inventories Decrease /-Increase0.00
R & D, Environmental and Other Expense0.00
Gain (Loss) on Disposition of Assets0.00
Share-based Compensation0.19
Income (Loss) from Equity Method Investments0.00
Financial Instruments and Foreign Currency Transaction0.00
Equity Method Investment Realized Loss On Disposal-
Cost Method Investments Realized Gains-
Trading Securities Realized Loss-
Employees Retention Credit-
Income taxes0.00
Unrealized Gain (Loss) on Investments0.00
Increase (Decrease) in Accounts Receivable0.00
Increase (Decrease) in Accounts Payable and Accrued Liabilities0.16
Accrued Expense0.00
Increase (Decrease) in Billing in Excess of Cost of Earnings0.00
Increase (Decrease) in Prepaid Expense0.00
Other Working Capital0.00
Other Noncash Income (Expense)0.00
Other net0.00
Payments for (Proceeds from) Other Operating Activities0.00
Discontinued operations0.00
Net Cash flow from Operating Activities-0.64
Investing Activities
Capital Expenditures0.00
Sale of Capital Items0.00
Proceeds from Sale and Maturity of Marketable Securities0.00
Payments to Acquire Trading Securities Held-for-investment0.00
Real Estate Investments0.00
Distribution To Shareholders In Connection With Purchase Of Fona Inc-
Restricted Cash and Investments Increase (Decrease)0.00
Payments for (Proceeds from) Loans0.00
Payments for (Proceeds from) Deposits0.00
Proceeds from Sale of Other Investments0.00
Payments for (Proceeds from) Federal Reserve and FHLB0.00
Cash Acquired from Acquisition0.00
Interest in Subsidiaries and Affiliates0.00
Sale of businesses0.00
Accounts payable0.00
Receivables0.00
Payments for (Proceeds from) Other Investing Activities0.00
Other Net0.00
Discontinued operations0.00
Net Cash Flow from Investing Activities0.00
Financing Activities
Short-term debt Net0.00
Other borrowing transactions0.00
Long-term debt - borrowings0.00
Long-term debt - repayments0.00
Federal Home Loan Bank and Federal Funds0.00
Issuances / -repurchases of Comm. Stock0.55
Partnership and Parent Transactions0.00
Issuances / -repurchases of Pref. Stock0.45
Deposits, Annuities, Contract Holders Funds0.00
Other financing activities net0.00
Other net0.00
Proceeds From Eidl And Ppp Loans-
Payments of Dividends, Preferred Stock and Preference Stock0.00
Dividends paid0.00
Net Cash Flow from Financing Activities1.00
Effect of exchange rate on cash flow0.00
Discontinued operations0.00
Free Cash Flow-0.64
Total Cash Flow0.36
4 historic quarters locked

Sign in to unlock the full Evolutionary Genomics Inc cash flow history.

Sign In Create Free Account

About Evolutionary Genomics Inc Quarterly Cash Flow Statement

What this statement shows

This page presents issuer-reported cash flow data, including operating, investing, financing, net, and free cash flow, as disclosed in SEC filings and normalized by CSIMarket.

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - normalization in the CSIMarket.com database.
  • Accession: 0001553350-23-000160

Figures are derived from filed reports and may be restated. Historical data is subject to revision.